Macrolides and drug-interactions: Review of literature;MACROLIDES ET INTERACTIONS MEDICAMENTEUSES: REVUE DE LA LITTERATURE

Therapie

Volumn 51, Issue 2, 1996, Pages 177-184

  Lauby, V ^a   Mallaret, M ^a   Dufrene I ^a   Amalfitano, G ^a   Stanke, F ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

adverse effects; drug interactions; macrolides

Indexed keywords

AZITHROMYCIN; BROMOCRIPTINE; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DIRITHROMYCIN; ERGOTAMINE; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; MIDAZOLAM; MIDECAMYCIN; QUINIDINE; ROXITHROMYCIN; SPIRAMYCIN; TACROLIMUS; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; WARFARIN;

ARTICLE; DRUG ABSORPTION; DRUG DEGRADATION; DRUG INTERACTION; DRUG MECHANISM; PRIORITY JOURNAL; CLASSIFICATION; HUMAN; REVIEW;

DRUG INTERACTIONS; HUMANS; MACROLIDES;

EID: 0030005399     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Sternberg RI, Baughman RP, First MR. Erythromycin-induced hearing loss in immunosuppressed transplant patients. Clin Transpl 1993; 7: 269-272.
2. Zhou Pann XR, Seree E, Zhou XJ et al. Involvement of human liver cytochrome P450 3 A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53 (21): 5121-5126.
3. Tobe SW, Siu LL, Jamal SA et al. Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995; 35: 188-190.
4. Miguet JP, Monange C, Vuitton D et al Une épidémie d'ictères due à l'association troléandomycine - contraceptifs oraux. Gastroenterol Clin Biol 1980; 4: 420-424.
5. Orme M, Back DJ, TjiaJ et al. The lack of interaction between clarithromycin and oral contraceptive steroids. Br J Clin Pharmacol 1990; 31 (2): 229.
6. Carry PV, Ducluzeau R, Jourdan C et al. De nouvelles interactions avec les macrolides ? Lyon Medical 1982 (30 oct): 189-190.
7. Zini R, Fournet MP, Barre J et al. In vitro study of roxithromycin binding to serum proteins and erythrocytes in humans. Br J Clin Pract 1988; 42 (Suppl 55): 54.
8. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Phamacokinet 1992; 23 (2): 106-131.
9. Pessayre D, Larrey D, Funck-Bruntano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16 (Suppl A): 181-191.
10. Delaforge M, Jaouen M, Mansuy D. Dual effects of macrolide antibiotics on rat liver cytochrome p450 induction and formation of metabolite-complexes: a structure activity-relationship. Biochem Pharmacol 1983; 32: 2309-2318.
11. Beaune P. Les cytochromes P450. Therapie 1993; 48: 521-526.
12. Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ 1989: 298: 572.
13. Gupta SK, Bakran A, Johnson RWG, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. BMJ 1989; 27: 475-481.
14. Petty B, Polis M, Haneiwich S et al. Pharmacokinetic Assessment of clarithromycin plus zidovudine in HIV patients. Anaheim Convention Center (California). Abstracts. 1992.
15. Lindsay J, Smith MA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 1990; 98: 222-223.
16. Schoewetter WF, Kelloway JS, Lindgren D. A retrospective evaluation of potential cardiac side-effects induced by concurrent use of terfenadine and erythromycin. J. Allergy Clin Immunol 1993; 53: 161.
17. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989; 86: 465-466.
18. Stramba-Badiale M, Guffanti S, Porta N et al. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am Heart J 1993; 126 (3): 740-744.
19. Reisz G, Pingleton SK, Melethil S, Ryan P. The effect of erythromycine on theophylline pharmacokinetics in chronic bronchitis. Am Rev Respir Dis 1983; 127: 581-584.
20. Ruff F, Prosper M, Pujet JC. Théophylline et antibiotiques. Absence d'interaction avec la josamycine. Therapie 1985; 2: 345-348.
21. Barbare J.C, Martin F, Biour M. Surdosage en théophylline et anomalies des tests hépatiques associés à la prise de josamycine. Therapie 1990; 45: 357-360.
22. Ruff F, Chu SY, Sonders RC, Senello LT. Effect of multiple doses of clarithromycin on the pharmacokinetics of theophylline. 30th Ann Intersc Conf Antimicrob Ag Chemother. Atlanta (Georgia). Abstracts. 1990.
23. Hashiguchi K, Niki Y, Soejima R. Roxithromycin does not raise serum theophylline levels. Chest 1992; 102 (2): 653-654.
24. Saint-Salvi B, Tremblay D, Surjust A, Lefehvre MA. A study of interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother 1987; 20 (B): 121-129.
25. Lavarenne J, Paire M, Talon O. Influence d'un nouveau macrolide, la midécamycine, sur les taux sanguins de théophylline. Therapie 1981; 36: 451-456.
26. Debruyne D, Jehan A, Bigot MC et al. Spiramycin has no effect on serum theophylline in asthmatic patients. Eur J Clin Pharmacol 1986; 30: 505-507.
27. Bachmann F, Jauregui L, Sides G, Sullivan TJ. Steady-states pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol 1993; 33 (9): 861-865.
28. Bachmann K, Nunlee M, Martin M et al. Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J Clin Pharmacol 1990; 30: 1001-1005.
29. Mitsch RA. Carbamazepine toxicity precipitated intravenous erythromycin. DICP 1989; 23: 878-879.
30. Vinçon G, Albin H, Demotes-Mainard F et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 1987; 32: 321-323.
31. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161-162.
32. Couet W, Istin B, Seniuta P et al. Effect of ponsinomycin on cyclosporin pharmacokinetics. Eur J Clin Pharmacol 1990; 39: 165-167.
33. Spindler A, Cheng J, Kindwall E, Charland S. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995; 57 (1): 89-94.
34. Grau E, Fontcuberta J, Félez J. Erythromycin-oral anticoagulants interaction. Arch Intern Med 1986; 146: 1639.
35. Auzépy Ph, Graïni L, Dechaubry V. Accident hémorragique grave par interaction josamycine-acénocoumarol. Réanimation Urgence 1993; 2 (2): 120-3.
36. Lauby V, Mallaret M, Amalfitano G et al. Interactions médicamenteuses liées à la clarithromycine. Réunion de la Société Française de Pharmacologie Clinique et Thérapeutique. Poitiers (France). Résumé. 1994.
37. Paulsen O, Nilsson LG, Saint Salvi B et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988; 63: 215-220.
38. Nelson MV, Berchou RC, Kareti D, Lewitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694-697.
39. Montastruc JL, Rascol A. Traitement de la maladie de Parkinson par doses élevées de bromocriptine. Interaction possible avec la josamycine. Presse Med 1984; 37 (13): 2267-2268.
40. Lagier G, Castot A, Riboulet G, Bosech C. Un cas d'ergotisme mineur semblant en rapport avec une potentialisation de l'ergotamine par l'éthylsuccinate d'érythromycine. Therapie 1979; 34: 515.
41. Grolleau JY, Martin M, De La Guerrande B et al. Ergotisme aigu lors d'une association josamycine/tartrate d'ergotamine. Therapie 1981; 36: 319-321.
42. Kemp JP. Decreased antihistamine metabolism. Ann Allergy 1992; 69: 533.
43. Moore N, Noblet C, Paux G. Torsades de pointes aux antihistaminiques H1. Therapie 1992; 47: 383-384.
44. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetic and electrocardiographic parameters. Drug investigation 1994; 7: 148-156.
45. Harris S, Hilligos DM, Colangelo PM et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995; 58(3): 310-315.
46. Jensen CWB, Flechner SM, Van Burren CT et al. Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin. Transplantation 1987; 43: 263-270.
47. Marre R, de Sousa G, Orloff AM, Rahmani R. In vitro interaction between cyclosporin A and macrolide antibiotics. Br J Clin Pharmacol 1993; 35: 447.
48. Azanza JR, Catalan M, Alvarez P et al. Possible interaction between cyclosporin ans josamycin: a description of three cases. Clin Pharmacol Ther 1992; 51: 572-575.
49. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporin and clarithromycin. J Heart Lung Transplant 1994; 13: 343-345.
50. Billaud EM, Guillemain R, Fortineau N et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990; 19 (6): 499-502.
51. Finielz P, Mondon JM, Chuet C, Guiserix J. Drug interaction between midecamycin and cyclosporin. Nephron 1995; 70: 136.
52. Kessler M, Netter P, Zerrouki M et al. Spiramycin does not increase plasma cyclosporin concentrations in renal transplant patients. Eur J Clin Pharmacol 1988; 35: 331-332.
53. Bachmann K, Sullivan TJ, Reese JH et al. The pharmacokinetics of oral cyclosporine A are not affected by dirithromycin. 34th ICAAC. Orlando. Abstracts. 1994.
54. Ljuti D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron 1995; 70: 130.
55. Aranko K, Olkkola KT, Hiller A, Saarnivaara L. Clinically important interaction between erythromycin and midazolam. Br J Clin Phamacol 1991; 33: 2178P.
56. Hugues FC, Lejeune CL, Munera Y. Therapeutic consequences of macrolide-induced inhibition of hepatic microsome. Semaine Hospitaliere Paris 1987; 63: 2280-2283.
57. Pollak T, Sketris I, McKenzie S, Hewlett T. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. DICP 1995; 29: 486-488.
58. Manila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single dose of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol 1993; 73: 180-185.
59. Mattila MJ, Vanakoski J, Idänpäan JJ. Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 1994; 47: 49-52.
60. Shaeffer M, Collier D, Sorell M. Interaction between FK506 and erythromycin. DICP 1994: 28: 280-281.
61. Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207-208.
62. Bartkowski R, McDonnell TE. Prolonged alfentanil effect following erythromycin administration. Anesthesiology 1990; 73: 566-568.
63. Bankowski RR, Goldberg ME, Huffnagle S et al. Sufentanil disposition. Is it affected by erythromycin administration? Anaesthesiology 1993; 78: 566-568.
64. Carson JL, Strom BL, Duff A et al. Acute hepatitis from sulfonamide and erythromycine. Clin Res 1992; 40: 554A.
65. Fleishaker JC, Phillips JP. Evaluation of potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol 1991; 31: 259-262.
66. Brannan M,Reidenberg P, Radwanski E et al. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographs evaluations. Clin Pharmacol Ther. 1995; 58 (3): 269-278.
67. Cortese LM, Gasser RA, Bjornson DC et al. Prolonged recurrence of pentamidine induced torsades de pointes. DICP 1992; 26(11): 1365-1369.
68. Lazzara R. Antiarrhythmic drugs and torsades de pointes. Eur Heart J 1993; 14 (Suppl H): 89-92.
69. Singh BN. Bepridil therapy: guidelines for patient selection and monitoring of therapy. Am J Cardiol 1992; 69 (11): 79D-85D.
70. Castot A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine. Lancet 1993; 341: 1541.
71. Astall MA, Hii JT, Lehman RG, Horowitz JD. Sotalol induced torsades de pointes: management with magnesium infusion. Postgrad Med J 1992; 68 (798): 289-290.
72. Montaz L. Torsades de pointes during sultopride poisoning. J Toxicol Clin Exp 1992; 12 (8): 481-486.
73. Fauchier JP, Fauchier L, Babuty D et al. Drug induced ventricular tachycardia. Arch Mal Coeur Vaiss 1993; 86 (5 Suppl): 757-767.
74. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP 1991; 25 (9): 1007-1008.
75. Redington K, Wells C, Petito F. Erythromycine and valproate interaction. Ann Intern Med 1992; 116: 877-878.
76. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolyse. Ann Intern Med 1988; 109: 682.
77. Bachmann K, Schwanz JI, Forney RB, Jauregui L. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol 1984; 46: 207-217.
78. Bachmann K, Schwanz JI, Fornay R et al. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol 1984; 46: 207-217.
79. Burger DM, Meenhorst PL, Mulder JW et al. Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. Drug Monit 1994; 16; 616-620.
80. Laforce CF, Szefler SJ, Miller MF et al. Inhibition of methyprednisolone elimination in the presence of erythromycin. J Allergy Clin Immunol 1983; 72: 34-39.
81. Funderberg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994; 151: 1840-1841.
82. Mogford N, Palette A. Erythromycin deafness and cimetidine treatment. BMJ 1994; 309: 1620.
83. Gaidano G, Berta L, Borio F et al. Administration de josamycine au cours de traitement par éthynilestradiol-cytoproterone acétate (EE2-CYPAc): interférence sur l'activité biologique des hormones circulantes et sur la capacité de liaison aux hormones sexuelles aux globulines plasmatiques (SHBG b.c). Médecine et Maladies infectieuses 1985; spécial: 37-40.
84. Romero S, Solaz C. Posible interacción entre josamicina y amitriptilina. Med Clin (Barc) 1992; 98: 279.
85. Brion N, Kollenbach K, Marion MH et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15 (3): 229-235.
86. Pollak PT, Sketris IS, MacEnzie SL, Hewlett TJ. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. DICP. 1995;: 486-488.
87. Orme M, Back DJ, Tjia J et al. The lack of interaction between clarithromycin and oral contraceptive steroids. Br J Clin Pharmacol 1988; 31 (2): 229.
88. Zündorf H, Wischmann L, Fassenbader M et al. Pharmacokinetics of clarithromycin and possible interaction with H2-blockers and antiacids. 31 st Intersci Conf Antimicrob Ag Chemother. Chicago (Illinois). Abstracts. 1991.
89. Nielsen OG. Roxithromycin. A new molecule, a new pharmacokinetic profile. Drug Invest 1991; 3 Suppl 3: 28-32.
90. Sides G, Cerimale B, Black H et al. Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 65-75.
91. Chave JP, Munafo A, Chatton JY et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics and effects on zidovudine disposition. Antimicrob Agents Chemother. 1992; 36: 1013-1018.